MTI Onyx V. Aneurysm Coil Trial Protocol Revisited; PMA On Track For 2004
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics' revised inclusion criteria for its U.S. pivotal trial comparing the Onyx LES liquid embolic system with Boston Scientific's GDC Ultrasoft coil to treat brain aneurysms will delay PMA filing by three fiscal quarters, MTI estimates
You may also be interested in...
MTI, FDA Revisit Onyx Aneurysm Trial Protocol: Enrollment Struggles Cited
Micro Therapeutics, Inc. is in discussions with FDA over revising its Onyx LES liquid embolic system brain aneurysm trial to better demonstrate efficacy in treating wide-necked aneurysms
MTI, FDA Revisit Onyx Aneurysm Trial Protocol: Enrollment Struggles Cited
Micro Therapeutics, Inc. is in discussions with FDA over revising its Onyx LES liquid embolic system brain aneurysm trial to better demonstrate efficacy in treating wide-necked aneurysms
FDA Neurology Panel Will Review MTI Onyx PMA Based On Coil Comparison
FDA's Neurological Devices Advisory Panel will meet Aug. 5 to review Micro Therapeutics' PMA for Onyx liquid embolic polymer to treat arteriovenous malformations (AVM)